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Science and technology have identified
unique properties in materials with dimen-
sions in the range of 1–100 nm [Health and
Safety Executive (HSE) 2004; National
Nanotechnology Initiative (NNI) 2004].
These properties may yield many far-reaching
societal benefits, but they may also pose
hazards and risks. One area of concern about
hazards is the workplace—be it a research
laboratory, start-up company, production
facility, or operation in which engineered
nanomaterials are processed, used, disposed,
or recycled. These are the workplaces in which
some of the first societal exposures to engi-
neered nanoparticles are occurring. Such
exposures are likely to be inadvertent and
unintended. Despite a conscious effort by
governments, corporations, nongovernmental
organizations (NGOs), trade associations, aca-
demics, and workers to anticipate and address
potential workplace hazards [Bartis and
Landree 2006; Hett 2004; National Institute
for Occupational Safety and Heath (NIOSH)
2006; National Science and Technology
Council (NSTC) 2006; Roco and Bainbridge
2003; Scientiﬁc Committee on Engineering and
Newly Identified Health Risks (SCENIHR)
2005], workers are still likely to be exposed
to nanomaterials. 
Much research on the ethical aspects of
nanotechnology has focused on generalized
issues such as equity, privacy, security, envi-
ronmental impact, and metaphysical applica-
tions concerning human–machine interactions
(Mnyusiwalla et al. 2003; Moor and Weckert
2004; Singer 2004). No ethics research has
been carried out that pertains specifically to
the workplace. To help anticipate the impact
of nanotechnology, it is important to provide
a framework for the ethical and scientific
issues involved with nanotechnology in the
workplace. Ethical analysis may assure society
that the expansive promise of nanotechnology
does not conceal hazards and risks for work-
ers. An emerging belief is that nanoscience
and technology cannot be based on past prac-
tices in which ethical and social reﬂection is a
second step to using newly developed science;
rather, ethical reflections must accompany
research every step of the way (National
Academy of Engineering 2004). Our goal in
this paper is to identify ethical issues that are
directly related to nanotechnology in the
workplace and their implications for workers’
health and safety.
Framework for Ethical
Assessment
The framework for considering the ethical
issues can be drawn from the work of Gert
et al. (1997), Gewirth (1978, 1986), and
Schrader-Frechette (1994) as well as from the
“principlist” approach of Beauchamp and
Childress (1994). The ethical issues that most
affect workers in jobs involving nanomaterials
are linked to identiﬁcation and communica-
tion of hazards and risks by scientists, author-
ities, and employers; acceptance of risk by
workers; implementation of controls; choice
of participation in medical screening; and
adequate investment in toxicologic and expo-
sure control research (Table 1). The ethical
issues involve the identification and assess-
ment of hazards and risks, nonmaleficence
(doing no harm), autonomy (self-determina-
tion), justice (fairness in distribution of risks),
privacy (in handling of medical information),
and respect for persons. 
Factual scientific knowledge—which is
the basis for ethical decisions about occupa-
tional safety and health—may be influenced
by biases and values (Kantrowitz 1995).
Scientific knowledge is unavoidably value
laden. No scientiﬁc theory can be considered
to be wholly objective, but one theory may be
more objective than another (Shrader-
Frechette 1994). Underlying the ethical deci-
sions are the way in which nanotechnology is
depicted, the potential beneﬁts, and the asso-
ciated hazards and risks. When information
about the hazards of nanoparticles is in doubt,
the critical question is where to draw the line
about the necessary level of protection and the
residual risk at a given level of protection. 
Risk assessments are partly subjective and
likely to be highly politicized. Thus all risk
projections are value laden. No single scenario
for describing risks and controls can suffice
because of the heterogeneous and develop-
mental nature of nanotechnology. The ethical
issues will be speciﬁc only for the knowledge
base at a given time and for a specified pro-
duction and use scenario. Researchers have
suggested that even with that type of speci-
ficity, alternative assessments are needed to
capture the ethical and political values that
inform policies such as those involving nano-
technology (Schrader-Frechette 2002).
Current State of Knowledge
about Nanotechnology
Hazards and Risks
The way in which nanotechnology is depicted
may inﬂuence society’s reactions to research,
development, and prevention and control of
potential nanomaterial hazards in the work-
place (Berube 2004). The term “nano-
technology” is misleading, since it is not a
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In the absence of scientiﬁc clarity about the potential health effects of occupational exposure to
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tion of hazards and risks by scientists, authorities, and employers; b) workers’ acceptance of risk;
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e) investment in toxicologic and control research. The ethical issues involve the unbiased determi-
nation of hazards and risks, nonmaleﬁcence (doing no harm), autonomy, justice, privacy, and pro-
moting respect for persons. As the ethical issues are identiﬁed and explored, options for decision
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grouping of physical, chemical, biological,
engineering, and electronic processes, materi-
als, applications, and concepts in which size is
the deﬁning characteristic (Aitken et al. 2004).
However, the issues of size, surface characteris-
tics, durability, chemical composition, and
other physiochemical features are not well
resolved in the deﬁnition. A fuller deﬁnition
also includes structures with novel properties
that can be manipulated on the atomic scale
(NNI 2004; Salamanca-Buentello et al. 2005). 
Nanoparticles can be considered in at least
two broad categories: engineered nanoparticles
and incidental (or adventitious) nanoparticles.
Engineered nanoparticles are designed with
very speciﬁc properties. Incidental nanoparti-
cles (natural and anthropogenic) are generated
in a relatively uncontrolled manner and are
usually physically and chemically hetero-
geneous compared with engineered nanoparti-
cles (NIOSH 2006). Although the four current
major production methods of engineered
nanoparticles (gas-phase synthesis, vapor depo-
sition, and colloidal and attrition methods)
may expose workers by inhalation, dermal
absorption,  and ingestion, the amount and
likelihood of worker exposure has not been
well established. The critical question (based
on the little information available) pertains to
the assessment of hazards and risks. The unify-
ing theme is that nanoparticles are smaller than
their bulk counterparts but have a larger sur-
face area and particle number per unit mass;
these characteristics generally increase toxic
potential as a result of increased potential for
reactivity (Aitken et al. 2004). The application
of that theory to the whole of nanotechnology
rather than to speciﬁc particles and processes
may increase rather than decrease the uncer-
tainty about hazards and risks. Increasingly,
other characteristics (e.g., surface characteris-
tics) in addition to particle size, that inﬂuence
toxicity are being identiﬁed (Donaldson et al.
2006; Warheit et al. 2004). These characteris-
tics are tremendously variable. Consequently, it
is useful to put some limits on the uncertainty
by being more precise in the language used to
describe nanoparticle hazards and risks.
Because a diverse mix of particles and processes
exists, hazards and risks are likely to be more
accurately assessed on a case-by-case basis—or
at least according to the type of production
methods and whether particles are embedded
in a matrix or unbound.
Knowledge about hazards and risks.
Health effects data on workers involved with
nanotechnology are limited because of the
incipient nature of the ﬁeld, the relatively small
number of workers potentially exposed to date,
and the lack of time for chronic disease to
develop and be detected. The most relevant
human experience deals with exposures to
ultraﬁne particles (which include particles with
diameters < 100 nm) and ﬁne particles (parti-
cles with diameters < 2.5 μm). Ultraﬁne and
ﬁne particles have been assessed in epidemio-
logic air pollution studies and in studies of
occupational cohorts exposed to mineral dusts,
fibers, welding fumes, combustion products,
and poorly soluble, low-toxicity particulates
such as titanium dioxide and carbon black
(Maynard and Kuempel 2005; Nel et al.
2006). The hazards of these exposures and
exposures to engineered nanoparticles are also
identiﬁed in animal studies (Donaldson et al.
2004, 2006; Elder et al. 2006; Lam et al. 2004,
2006; Oberdörster et al. 2005; Shvedova et al.
2005; Warheit et al. 2004). A strong relation-
ship exists between the surface area, oxidative
stress, and proinﬂammatory effects of nanopar-
ticles in the lung. The greater the oxidative
stress, the more likely the risk of inﬂammation
and cytotoxicity (Nel et al. 2006; Oberdörster
et al. 2005). The ﬁndings from animal studies
ultimately need to be interpreted in terms of
the exposure (dose) that humans might receive.
Although there is still some debate, the evi-
dence from air pollution studies associates
increased particulate air pollution (the finer
particulate matter fraction, PM2.5, with an
aerodynamic diameter < 2.5 μm) with adverse
health effects in susceptible members of the
population—particularly the elderly with respi-
ratory and cardiovascular diseases [Mark 2004;
Peters 2005; U.S. Environmental Protection
Agency (U.S. EPA) 2004]. Moreover, the con-
centrations associated with measurable effects
on the health of populations are quite low
(Aitken et al. 2004).
In occupational studies, the populations
that are repeatedly exposed to hazardous min-
eral dusts and fibers in the respirable range
(e.g., quartz and asbestos, respectively) have
well-known health effects related to the dose
inhaled (Maynard and Kuempel 2005). With
asbestos, the critical risk factors for develop-
ing respiratory diseases are ﬁber length, diam-
eter, and biopersistence. For poorly soluble,
low-toxicity dusts such as titanium dioxide,
smaller particles in the nanometer size range
appear to cause an increase in risk for lung
cancer in animals on the basis of particle size
and surface area (Heinrich et al. 1995;
Oberdörster et al. 2005; Tran et al. 2000). 
Although the ﬁndings are not conclusive,
various studies of engineered nanoparticles in
animals raise concerns about the existence and
severity of hazards posed to exposed workers
(Kipen and Laskin 2005). Possible adverse
effects include the development of ﬁbrosis and
other pulmonary effects after short-term expo-
sure to carbon nanotubes (Lam et al. 2006;
Oberdörster et al. 2005; Shvedova et al. 2005),
the translocation of nanoparticles to the brain
via the olfactory nerve, the ability of nanoparti-
cles to translocate into the circulation, and the
potential for nanoparticles to activate platelets
and enhance vascular thrombosis (Radomski
et al. 2005). 
None of these findings are conclusive
about the nature and extent of the hazards, but
they may be sufﬁcient to support precautionary
action.
Ultimately, the signiﬁcance of hazard infor-
mation depends on the extent to which workers
are exposed to the hazard. This is the deﬁning
criterion of risk (the probability that an exposed
worker will become ill). A need has been identi-
ﬁed for nanoparticle-speciﬁc risk assessments
(i.e., those that use the most appropriate dose
metrics rather than typical mass) that will be
unique to nanotechnology (National Academy
of Engineering 2004; SCENIHR 2005). 
Risk assessment has been widely used to
manage the uncertainty of risks posed to
humans by newly introduced chemicals or
processes. However, nanotechnology encom-
passes a diverse range of compositions, struc-
tures, and applications, so a single risk
assessment and management strategy may not
be appropriate (Wardak and Rejeski 2003).
Nanotechnology involves the manipulation of
matter at the nanoscale to produce materials,
structures, and devices that contain various
particle types, sizes, surface characteristics, and
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Table 1. Ethical issues pertaining to workplace situations involving nanomaterials.
Work-related scenarios Ethical principles involved Decisionmaking issues
Identiﬁcation and  Responsibilities of scientists Extent to which strengths and weaknesses of data 
communication of  Nonmaleﬁcence are identiﬁed
hazards and risks Autonomy Degree of participation in public discussion
Respect for persons Accuracy of communications
Timeliness of communications
Workers’ acceptance  Autonomy Extent of inclusion of workers in decisionmaking
of risks Respect for persons
Justice
Selection and  Nonmaleﬁcence Level of control technologies utilized
implementation of  Beneﬁcence
workplace controls Respect for persons
Medical screening  Autonomy Appropriateness of the rationale for medical screening
of nanotechnology  Privacy Extent to which participation is voluntary
workers Respect for persons Maintenance of privacy test results
Investment in  Nonmaleﬁcence Adequacy of investment
toxicological and  Justice
control research Respect for personscoatings. These particles may best be addressed
by a range of risk assessments specific to the
type of particle (composition, surface charac-
teristics, and shape) being assessed. Because of
the general inverse relationship between parti-
cle size and surface area, dose–effect relation-
ships may vary as a function of total surface
area and number of particles rather than mass
units (SCENIHR 2005). Risk assessments will
be useful to the extent that they reflect the
effects of particle sizes and surface area, but
such assessments may also need to reﬂect other
particle characteristics. Moreover, it is cur-
rently unclear the extent to which the toxico-
kinetics (an important component in risk
assessment) can be predicted from knowledge
of physicochemical properties of nanoparticles
(SCENIHR 2005).
Evidence base for hazard controls. The
most frequently used model of the workplace
environment identiﬁes sources of hazards and
routes of exposure (e.g., inhalation, skin)
[Office of Technology Assessment (OTA)
1985]. Control can be introduced at each of
these points. Occupational safety and health
professionals have identified a hierarchy of
controls based on reliability, efficiency, and
the principle that the environment should be
controlled before the worker is required to
take any preventive action (OTA 1985). In its
simplest form, the hierarchy of controls speci-
ﬁes that engineering controls (including sub-
stitution, enclosure, isolation, and ventilation)
are preferred to the use of personal protective
equipment (such as protective clothing and
respirators). Work practices are frequently
incorporated in risk management efforts to
minimize worker exposures, and they often
supplement the use of engineering controls.
Administrative controls such as worker rota-
tion are sometimes included and generally
constitute the “third line of defense” when
engineering controls and work practice con-
trols cannot achieve the desired level of worker
protection (OTA 1985).
In the absence of adequate toxicity informa-
tion and extensive history of engineered nano-
materials use, the rationale for control guidance
has been based on experience in controlling
exposures to incidental ultraﬁne particles and
gases. Airborne nanoparticles are considered to
have no inertia—hence, they will behave simi-
larly to gases and will diffuse if they are not
fully enclosed (Aitken et al. 2004). A rich his-
tory of aerosol science describes the fundamen-
tal properties of aerosols and their control
[American Conference of Governmental
Industrial Hygienists (ACGIH) 2001; Brown
1993; Burton 1997; Davies 1966; Friedlander
1977; Fuchs 1964; Hinds 1999; Ratherman
1996]. Although ultraﬁne particles are consid-
ered equivalent to nanoparticles by some
authorities (SCENIHR 2005), they are usually
(but not exclusively) at the upper end of the
nanoscale range. If airborne nanoparticles con-
form to the classical physics and aerodynamics
observed for larger particles, then controls effec-
tive in capturing ﬁne and ultraﬁne particles and
gases (such as source enclosure, local exhaust
ventilation, and personal protective equipment)
should be effective with the current generation
of nanomaterials. It is reasonable to believe that
most control methods used for ﬁne and ultra-
ﬁne particles and also for gases will be useful for
controlling nanoparticles, but there is no reason
to expect that application of these methods to
new nanoparticle generation processes will
result in better control than that previously
demonstrated for microscale powders and gases
(Aitken 2004). A considerable body of opinion
indicates that the adverse effects of nanoparti-
cles cannot be predicted (or derived) from the
known toxicity of bulk materials with similar
chemical composition and surface properties
(SCENIHR 2005). Control options for
nanoparticles range from no controls to the use
of isolation and containments practiced with
radiation, gases, and biological agents. The
question is where in this continuum should
controls be selected. This may also translate
into how much money to invest in them.
When risks are known to be high or low, the
decision is relatively easy, and the appropriate
control strategies are generally apparent.
However, when hazards are uncertain (as they
are with nanoparticles), the difficulty is in
deciding what level of controls is warranted
(Figure 1). Given the paucity of toxicity infor-
mation, control guidance must be regarded as
interim, and some authorities believe that it
should be precautionary—that is, tending
toward reducing exposures as much as possible
(HSE 2004). 
Summary of evidence on hazards and con-
trols. The evidence base pertaining to nan-
otechnology hazards and controls has been
reviewed in various publications (Hett 2004;
Maynard and Kuempel 2005; National
Academy of Engineering 2004; NIOSH,
2006; Royal Society and Royal Academy of
Engineering 2004; SCENIHR 2005) and is
summarized in Table 2 by four categories of
Nanotechnology in the workplace
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Table 2. Summary of the state of knowledge for nanoparticle hazards and controls.
Awareness of knowledge Content of knowledge (hazards and controls)
1. What we know we know Health effects of ultraﬁnes, air pollution, and ﬁbers
How to control ultraﬁne particles in the workplace
Importance of size, surface area, and surface characteristics
Serious health effects of some nanoparticles in animals
Translocation of some nanomaterials along the olfactory nerve in animals
2. What we know we don’t know Measurement and characterization techniques
Hazards of newly engineered particles
Extent of translocation in the body
Interaction with contaminants in the workplace
Importance of dermal exposure
Health effects in workers
Risks to workers
Effectiveness of controls
Advisability of medical screening and biological monitoring
Risk to workers’ families
3. What we don’t know we know Extensive experience available in controlling hazardous substances and 
agents (radiation, biological agents, pharmaceuticals) that can be 
applicable to nanoparticles
Proprietary nanoparticle information
Lessons from previous “new” technologies
4. What we don’t know we don’t know Unanticipated new hazards
Unanticipated new controls
Wrong assumptions about hazards and controls
Adapted from Drew (1999) and Schulte et al. (2004).
Figure 1. Risk management decisionmaking for nanoparticles in the workplace: what is the appropriate
level of controls?
Less
certain More precautionary
Less
precautionary
More certain
Use of a
nanomaterial
Risk communication
and management
Hazard
identification
and risk
assessmentknowledge described in terms of hazards and
controls and awareness. These categories are
mutable and pertain to the state of knowledge
at a given time. Category 1 (“what we know
we know”) indicates that we have some
knowledge about the health hazards posed by
some types of nanoparticles (e.g., ultraﬁne par-
ticles) and gases and how to control them.
This category applies to the current generation
of engineered nanoparticles and is the basis for
much of the current guidance. Category 2
knowledge (“what we know we don’t know”)
is the basis for much of the research currently
being conducted or planned. In general, we do
not know much about the hazards of new or
anticipated engineered particles or whether
enough precautions have been taken. A major
question is not only how to control exposure
but also what are the appropriate extent and
cost of controls. Category 3 knowledge (“what
we don’t know we know”) represents the
under-utilization of established knowledge.
That is, scientists have had extensive experience
in hazard and exposure control for ionizing
radiation, biological agents, pharmaceuticals,
grain and mineral dusts, and air pollution.
This experience could be more directly
brought to bear on controlling the hazards of
nanomaterials in the workplace. In addition,
this category could include proprietary infor-
mation about nanoparticles that is not avail-
able for hazard assessments. Category 4
knowledge (“what we don’t know we don’t
know”) represents a perennial area of philo-
sophical exploration (Caws 1998). This cate-
gory includes the range of scenarios about the
potency of hazards and the extent of risks.
Will new scenarios present new types of expo-
sures and risks? The popular literature on
nanotechnology is replete with characteriza-
tions of possible future scenarios, but no pro-
jections have been made of workplace hazards
and risks (Drexler 1986; Regis 1995).
Category 4 knowledge also includes the lack of
awareness of factors inﬂuencing an issue. This
lack of awareness can be addressed by engag-
ing a wide variety of disciplines and communi-
ties of interest to characterize an issue (HSE
2004). Category 4 knowledge also includes
the beliefs we hold that may be wrong. Such
beliefs could lead to taking or not taking pro-
tective measures on the basis of faulty assump-
tions. Eventually, Category 4 knowledge can
be transformed to Category 2 and then to
Category 1.
Regardless of which type of knowledge is
considered, the ultimate ethical requirement is
to accurately portray the state of knowledge
about a hazard or risk and not to understate or
overstate it. However, given the developmen-
tal nature of nanotechnology, the knowledge
of hazard potential will change over time and
require restatement and possibly modiﬁcation
of guidance. In the absence of adequate hazard
and risk assessment data, the critical question
is how much caution is warranted.
Ethical Issues
Identifying and communicating hazards and
risks. The “hazard identiﬁcation” stage of risk
analysis is the basis for risk management deci-
sionmaking. The output of this stage is often
highly debated, since the process of reasoning
is primarily qualitative and the results trigger
other stages of analysis and decisions about
preventive action (Crawford-Brown and
Brown 1997). Interpreting scientiﬁc informa-
tion about the hazards of nanomaterials is
basic to communicating the hazards and risks
posed to workers. Interpreting and communi-
cating hazard and risk information is an inte-
gral part of risk management by employers.
The employers’ decisionmaking will focus on
deciding which preventive controls should be
used to assure a safe and healthful workplace. 
Employers and workers look to scientists
and authoritative organizations to help inter-
pret hazard and risk information and to put it
into context. This expectation may pressure
scientists to go beyond the mere conduct of
research. The interface between science and
morality is exceedingly complex, but scientists
are generally considered to have ethical
obligations to society at large (Pimple 2002;
Schrader-Frechette 1994; Weil 2002).
However, no consensus has been reached
about the nature of those ethical obligations
beyond fulﬁlling the professional responsibili-
ties internal to scientiﬁc research. Framing a
clear and coherent approach to the ethical
responsibilities of scientists in nanotechnology
is a difficult task. At the least, such an
approach requires scientists to use appropriate
qualiﬁers in published papers and to be cau-
tious in generalizing their results. More
broadly, it means not shrinking from consid-
ering the implications of their work, even if
all the scientiﬁc details are not known. 
Decision makers may have inadequate sci-
entiﬁc information to help them decide how
precautionary their approach should be
(Cairns 2003). To determine whether a deci-
sion conforms with the principle of non-
maleﬁcence, decision makers must determine
the harm that could occur if the nanoparticles
were as toxic as suggested by preliminary haz-
ard information. Data on air pollution and
industrial ultrafine particles indicate that a
given mass of nanoparticles would be more
biologically reactive and hence potentially
more toxic than the same mass of larger parti-
cles (Seaton 2006). Consequently, the level of
control might need to be more stringent for
smaller nanoscale dusts than for those with
diameters > 100 nm. Ultimately, the more
stringent level of controls may result in risks
that are equal to or smaller than risks posed
by larger particles. Authoritative organizations
and employers are responsible for communi-
cating the risk workers face after appropriate
controls are implemented. Failure to do so
may preclude workers from exercising auton-
omy. This issue may be confounded by the
fact that the employer has a proprietary inter-
est in not releasing information about
“nanoproducts” and workplace controls.
The principlist ethical approach focuses on
principles such as nonmaleﬁcence and auton-
omy but fails to assess the social and organiza-
tional context of occupational safety and
health and the role of practitioners in relation
to the corporate structure (Gert et al. 1997;
Samuels 2003). With regard to nanotechnol-
ogy, the contextual pressures on practitioners
and authorities arise from a company’s or soci-
ety’s needs and desires for nanotechnology to
grow and develop. Mention of potential
health concerns may be seen as alarmist,
unfounded, and detrimental to the growth of
the ﬁeld. Nonetheless, the counter position is
that conflicting demands on practitioners
from being both an agent of a company and
an autonomous professional constitute a social
and structural problem rather than a problem
of individual ethics (Draper 2003; Samuels
2003). One solution is that health pronounce-
ments be made independently of promotional
concerns for nanotechnology.
Workers’ acceptance of risk. Acceptance of
risk is a relative concept that includes judg-
ment about the certainty and severity of risk,
the extent of the health effects, voluntary
nature of the risk, the risks and advantages of
any alternatives, and compensation for under-
going the risk (Fischoff 1994). It is a false
premise to assert that workers have free choice
in terms of which work and working condi-
tions to accept. Although some component of
self-determination is present, economic and
social conditions exert the greatest inﬂuences
on workers’ selection of work, level of risk tol-
erated, and ability to participate in risk man-
agement. Worker participation in risk
management is not a static concept and has
increased over the past 35 years with the
implementation of team approaches, manage-
ment systems, corporate responsibility, and
right to know and act movements (Gallagher
1997; Jensen 2002; Lynn 1997; Shearn
2005). Nonetheless, workers generally cannot
universally refuse work they consider haz-
ardous and still keep their jobs. Conformance
with the principle of autonomy depends on
the extent to which workers have input into
risk management at their work sites and the
degree to which they are at risk after controls
have been implemented.
Justice is also related to worker decision-
making. At issue is the extent to which work-
ers are exposed to greater risks than the general
public—or, stated another way, whether it is
appropriate to exchange incentives such as
Schulte and Salamanca-Buentello
8 VOLUME 115 | NUMBER 1 | January 2007 • Environmental Health Perspectiveswages or hazardous duty pay for additional
risk from exposure to nanoparticles (Schrader-
Frechette 2002). This issue may be less signiﬁ-
cant if nanoparticle controls reduce workers’
risk levels to those of the general public, if
conceivably both are known. Clearly, society
accepts that some jobs are inherently riskier
than others. However, in many countries the
societal goal is to provide a safe and healthful
workplace for all workers.
Selecting and implementing controls. The
critical ethical question related to control of
nanoparticles is whether sufﬁcient controls are
being implemented to prevent injury and ill-
ness. If not, worker exposures may result in
increased risk of harm or actual harm. The
central scientiﬁc fact is that the risk posed by
nanomaterials is not well established. However,
preliminary information suggests that at least
the same level of concern afforded to industrial
ﬁne and ultraﬁne particles should be extended
to engineered nanomaterials and that a com-
mensurate level of protection should be insti-
tuted for them (Hett 2004; Royal Society and
Royal Academy of Engineering 2004; Seaton
2006). Any risk posed by exposure to ultraﬁne
particles is a function of their potential toxicity
and the extent of exposure. Based on limited
toxicological evidence of risk and a heightened
level of concern, the best approach might be to
treat engineered nanoparticles as if they were
potential occupational hazards and to use a
prudent health-protective, risk-based approach
to develop interim precautionary measures
consistent with good professional occupational
safety and health practice (Royal Society and
Royal Academy of Engineering 2004). 
Such interim precautionary measures
could include guidelines for conducting work-
place exposure assessments, implementing
engineering controls, designating work prac-
tices, and developing process or industry
interim exposure limits as core elements. If the
focus of exposure control is airborne particles
of respirable dimensions, such approaches may
be useful and reﬂect the professional judgment
of experienced practitioners. If skin absorption
is also a likely route of exposure, guidelines
should be developed for preventing skin expo-
sure. Unfortunately, data are insufficient to
make a strong risk-based assessment to inform
these decisions.
The evidence suggests that at least some
manufactured nanoparticles will be more
toxic per unit of mass than larger particles of
the same chemicals (Royal Society and Royal
Academy of Engineering 2004). However,
some evidence indicates that with the use of
existing controls for ﬁne or ultraﬁne particles,
workers will not be at inordinately elevated
risk for lung disease. For example, estimates
based on animal studies indicate that workers
exposed to ultrafine titanium dioxide at
0.1 mg/m3 for a 45-year working lifetime
have an excess risk of lung cancer that is
< 1/1,000 and could in fact have a risk
approaching zero (Kuempel et al. 2004). The
basis for these ﬁndings is the hazard posed by
increased particle surface area for a given mass
of small-sized particles, as derived from ani-
mal studies and extrapolated to humans. The
extent to which this analysis pertains to other
nanoparticles is not known and may vary
depending on morphology, surface activity,
and biopersistence. Moreover, precise risks
from exposure to these ultraﬁne particles can
be determined only if adequate animal or
human data are available. Also, if particles can
translocate into the central nervous system or
the circulatory system, further estimates will
be required before conclusions can be drawn
(Oberdörster et al. 2005).
In short, given the insufﬁcient evidence of
hazards posed by the current generation of
nanoparticles, the risks (whatever they may be)
are expected to be reduced when controls rec-
ommended for known industrial ultraﬁne par-
ticles (such as titanium dioxide) are utilized.
This conclusion is supported by a) a general-
ized risk assessment based on surface area for
poorly soluble, low-toxicity particles and
b) the fact that such particles conform to clas-
sic physics and aerodynamic laws when air-
borne. However, future assessments of risk
could be different, depending on the bio-
persistence, structure, surface activity of new
particles, and information about translocation
across endothelial cell barriers. If these topics
are the focus of risk communications and
management efforts, there appears to be gen-
eral conformance with the ethical principles of
beneﬁcence and nonmaleﬁcence. At the same
time, no strong evidence indicates that work-
ers in these environments are not at excess
risk. Minimal risk is only assumed on the basis
of qualitative risk assessments and the utility
of proven controls for some types of particles. 
Overall, the knowledge base pertaining to
nanomaterials is not static but changes as sci-
entists develop new materials and conduct
toxicological or other health effects research.
Consequently, ongoing evaluation of health
risks is needed along with continued commu-
nication and development of management
plans to be in conformance with the ethical
principles discussed in this article.
Establishing medical screening programs.
Medical screening is the application of tests to
asymptomatic persons to detect those in the
early stages of disease or at risk of disease.
Medical screening in the workplace differs from
medical screening in the general population
because of the specific nature of the occupa-
tional condition and responsibilities of employ-
ers (Halperin et al. 1986; Harber et al. 2003). A
wide range of ethical questions has been identi-
ﬁed regarding the medical screening of workers
and the use and implications of the findings
(Ashford et al. 1990; Schulte 1986). These
questions address the rationale for screening,
the voluntary nature of the screening, the action
that will be taken for workers with positive
tests, and individuals who will have access to
test information. 
Medical screening is not generally war-
ranted when the toxicity of a material and the
workers’ risk are unknown—as is the case with
most nanomaterials. Moreover, for diseases
such as lung cancer (which is a potential out-
come resulting from some nanoparticle expo-
sure), no strong evidence base exists for
routine screening; and general population
screening for lung cancer is not generally rec-
ommended [National Cancer Institute (NCI)
2006]. Not only does screening fail to reduce
mortality from lung cancer, it could lead to
false-positive tests and unnecessary invasive
procedures or treatments (NCI 2006).
Medical screening of workers may be war-
ranted for nonmalignant respiratory effects in
some nanotechnology operations where signif-
icant residual risks may occur after controls are
implemented. Such screening should be part
of a comprehensive risk management program
that considers not only respiratory hazards but
also cardiovascular and neurologic risks as well
as risks in various other potential target organ
systems (Oberdörster et al. 2005; Radomski
et al. 2005; Tran et al. 2005). If various nano-
materials are found to have toxic effects and if
appropriate (validated) tests exist for early
detection of those effects in exposed workers,
medical screening might be warranted.
However, medical screening is historically
viewed as a secondary preventive effort in the
hierarchy of controls (Ashford et al. 1990)
The ethical questions that apply to the
medical screening of workers pertain to
whether the screening is voluntary, who will
have access to the results, and what the pur-
pose of such access will be. Screening gener-
ally requires diagnostic conﬁrmation; and for
positive cases, screening requires timely treat-
ment. Who is ﬁnancially responsible for these
procedures? Ethical issues can also arise in the
use of screening results to label or stigmatize
workers or to remove them from a job.
Screening results may also create psychologi-
cal burdens. Resolving such ethical issues will
depend partly on the degree to which the
worker has been informed about how the
results will be used. 
Ensuring adequate investment in toxico-
logical and control research. Ethical issues
cannot be adequately addressed for nanotech-
nology without sufficient knowledge of the
hazards involved. Because limited information
is available on the safety of an ever-growing
number of nanomaterials, an ongoing research
effort is needed to comport with the principles
of autonomy, beneficence, and nonmalefi-
cence. In addition, research is needed on the
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controls. Internationally, such research is
under way. 
However, the question of the level of
funding of this research has ethical implica-
tions because much of the current control
guidance is precautionary and is not based on
strong quantitative risk assessments. Further
research is the only way to address this lack of
appropriate information. 
Some commentators have called for a
slowdown in research and development of
nanoparticles, whereas others have identiﬁed a
need for increased health effects research and
ethical analysis [Action Group on Erosion,
Technology and Concentration (ETC
Group) 2003, 2004; Mnyusiwalla et al.
2003]. The needs for health-based research
have been identified and include the follow-
ing topics: exposure and dose, toxicity,
metrology, epidemiology, control technology,
safety, education, recommendations, and
applications in the near term (NIOSH 2006). 
Researchers could help further the discus-
sions of ethical issues by assessing the global
budget for nanotechnology research and
development and by determining the actual
amounts dedicated to occupational safety and
health research and ethical research in this
field. Globally, such information is not well
documented; but existing U.S. data can be
considered. For the ﬁrst time since the incep-
tion of the NNI, funding for 2005 was classi-
fied by program component area. The
funding for the Societal Dimensions compo-
nent area included $US39 million for envi-
ronment, health, and safety and $43 million
for educating the public about the broad
implications of nanotechnology for society
(including economic, workplace, education,
ethical, and legal implications). This funding
came from 11 agencies with a combined
nanotechnology budget of approximately
$1.054 billion. The level of funding (7.8% of
the total) has been criticized as insufﬁcient for
the societal dimensions component and the
subset dedicated to occupational safety and
health (Bartis and Landree 2006; Maynard
2006; Service 2005). Nonetheless, there is a
concerted international effort to address
health and safety aspects of nanomaterials
(NSTC 2006; Thomas et al. 2006).
Promoting respect for persons. Underlying
the debates about nanotechnology has been the
issue of tolerating the potential for harm to
some in the context of anticipated beneﬁts to
society. Such thinking embodies the utilitarian
point of view that harm to one person may be
justified by a larger benefit to someone else
(Harris 2003). This point of view contrasts
with the ethical principle of respect for persons,
which emphasizes the rights of the individual
and is associated with the golden rule (“Do
unto others as you would have them do unto
you”) (Gewirth 1978, 1986). In the workplace,
this principle translates to acknowledging for
each worker the right to a safe and healthful
work environment. This right imposes correla-
tive duties on the employers and governments
who must secure the workers’ rights to a safe
and healthful workplace (Gewirth 1986). The
objection to this interpretation is that the
rights of employers, and hence the rights of
society, to property and beneﬁt resulting from
nanotechnology may be (or may appear to be)
in conflict with workers’ rights. When two
rights conﬂict with each other, some rational
way must be found to determine their relative
priority. Gewirth (1986) identiﬁed an essential
criterion for such priority as the degrees of
necessity for action. For example, where the
property rights of employers may be in con-
ﬂict with workers’ rights to safety and health,
the diminution of health or a threat to safety
lowers one’s capacity for action and is a greater
loss than some decrease in another’s property,
wealth, or freedom to control it. The practical
implication is this: In the absence of adequate
information about nanotechnology hazards,
risks, and controls, employers should be
moved to use more rather than fewer control
measures (Hett 2004). Conducting site-
specific hazard assessments and using appro-
priate controls appear to demonstrate
conformance with the principle of respect for
persons and with the principles of autonomy,
beneficence, and nonmaleficence. However,
the extent of control measures required may
be the key matter of dispute. For the most
part, control of the current generation of most
engineered nanoparticles is within the capabil-
ities of existing technologies. The issue is how
much to invest in applying those technologies
in a given workplace.
Strategies for Supporting
Ethical Decisionmaking 
Placing special emphasis on small businesses.
The occupational safety and health problems
of small businesses have been a major focus of
concern, particularly in the last decade, since
most workplaces are classified as small (i.e.,
workplaces that employ fewer than 250, 100,
or 20 workers, depending on the deﬁnition).
This statement is likely to hold true for work-
places involving nanotechnology, but it is not
well documented (Aitken et al. 2004; Roco
and Bainbridge 2003). The frequency of occu-
pational injury and illness in small businesses
may exceed the average for general industry
across all businesses in a sector, but the fre-
quency may not be evident in an individual
company (NIOSH 1999). Small businesses
are generally perceived to have little time and
few resources dedicated to occupational safety
and health. 
Small businesses are the driving force of
most economies, including the subset of
economies related to nanotechnology (Roco
and Bainbridge 2003). Independent consul-
tants, trade associations, insurance companies,
product suppliers, and government agencies
are the major sources of occupational safety
and health information for small businesses.
Occupational safety and health information
may also be passed to downstream users of
nanoparticles from upstream suppliers. In fact,
for documented hazards, suppliers may have
an ethical or legal obligation to pass on such
information to downstream customers. There
is a need for occupational safety and health
guidance information about nanotechnology
hazards and controls for small businesses.
Adopting a global perspective. The growth
of nanotechnology is a global phenomenon
that requires a global approach to hazards and
risks, particularly in the workplace. The world
needs internationally valid standards for
nanotechnology materials as well as a uniform
nomenclature (American Society for Testing
and Materials 2005; Hett 2004). Without a
uniform nomenclature, investigators, insurers,
regulators, governments, companies, and
workers could have difﬁculty communicating
and taking concerted actions. 
The ﬂow of materials in the global econ-
omy crosses many borders, including those of
developing nations (Salamanca-Buentello
et al. 2005). Thus, to assure the safety and
health of workers, decision makers (whether
they are employers or government authorities)
must know and understand what materials
are used in various processes and operations.
This issue is complicated because many differ-
ent deﬁnitions and descriptions may be used
in science-based and regulation-based docu-
ments. To develop nanotechnology with min-
imal risks, knowledge gaps must be identiﬁed
and addressed through international coopera-
tion. Also needed is a transparent risk assess-
ment framework that can achieve wide
acceptability (SCENIHR 2005).
Global approaches to sharing occupational
safety and health information require increased
opportunity and capacity to access informa-
tion. The “right” to know about risks—or
more broadly, the right to information—is not
evenly recognized worldwide (Pantry 2002).
The World Health Organization (WHO) pro-
motes the right to health at work for all.
Information is a means to realizing that right.
Despite broad WHO membership by many
countries, true access to information and distri-
bution within countries is still a problem.
Risk communications (including material
safety data sheets) should reflect a degree of
uniformity worldwide. International collabora-
tion is warranted to ensure that hazardous
processes are not relegated to countries with
cheap labor markets or lax environmental con-
trols (Singer et al. 2005, 2006). A critical issue
that has both national and global implications
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made of a given substance differently from
materials made with larger particles of the same
substance. The characteristics of nanoparticles
may be different from those of the larger parti-
cles with the same composition. For example,
most materials made from carbon generally
appear to pose a minimal health risk; however,
nanotubes made of carbon may pose a greater
health risk yet be regulated at the less protec-
tive level (Shvedova et al. 2005). The issue is
whether to recommend the same risk commu-
nication and management strategy for both.
On the basis of the carbon nanotube example,
new standards and risk communication materi-
als are likely to be required for at least some
nanoparticles.
Conclusions
The ethical questions about nanotechnology
in the workplace arise from the state of knowl-
edge about the hazards of nanomaterials and
the risks they may pose to workers. The lack
of clarity on these issues requires an interim
assessment of the hazards and risks that might
exist in various situations. Workers will be
able to exercise their autonomy only if the
processes leading to hazard identiﬁcation and
risk assessment are transparent and under-
standable. Employers will conform to the
principles of autonomy, beneficence, non-
maleficence, justice, privacy and respect for
persons to the extent that they a) accurately
portray hazards and risks, b) are precautionary
in their approach to hazards, c) engage in
communication and dialogue with workers,
and d) take the necessary steps to control risks
so that they appear reasonable and acceptable
to workers.
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